InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company specializing in anti-inflammatory therapies targeting the complement system, will be attending several events in San Francisco, California, during the week of January 13, 2025, coinciding with the 43^rd Annual J.P. Morgan Healthcare Conference.

LifeSci Partners Corporate Access Event
Individual meetings will be held on January 14 and 15, 2025.

Biotech Showcase 2025
A workshop titled, The Need for Novel Responses to Disease Threat(s) in a Fast-Changing World: A Q&A with Government, NGO and Industry Participants, is scheduled for January 15, 2025, from 8:00 – 9:00 AM PT.

About InflaRx

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company developing novel anti-inflammatory treatments using proprietary anti-C5a and anti-C5aR technologies. These technologies are used to create highly effective and selective inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a key inflammatory mediator in various inflammatory diseases. The company’s lead candidate, vilobelimab, is a first-in-class, intravenously administered, anti-C5a monoclonal antibody that specifically targets free C5a. It has shown disease-modifying clinical activity and good tolerability in several clinical trials across different indications. InflaRx is also developing INF904, an oral small molecule C5a receptor inhibitor. Established in 2007, InflaRx has offices and subsidiaries in Jena and Munich, Germany, and Ann Arbor, Michigan, USA. For more information, please visit .

InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (collectively, InflaRx).

Contacts:

FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements that are not historical facts are considered forward-looking statements, often indicated by words like “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue.” Such statements, found throughout this release, address our intentions, beliefs, projections, outlook, analyses, and current expectations, and include the risks, uncertainties, and other factors detailed in the “Risk factors” and “Cautionary statement regarding forward-looking statements” sections of our SEC filings. These statements are current only as of the release date and involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Because of these risks and uncertainties, you should not over-rely on these forward-looking statements. We are not obligated to update these statements, except as legally required.